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To the Editor:
The review by Castera et al. [1] presents signiﬁcant
interest to the community as it reports a non-invasive
evaluation of liver ﬁbrosis using transient elastography
(TE). Indeed TE is becoming an important tool in the fu-
ture practice of hepatology to assess hepatic ﬁbrosis in pa-
tients with chronic liver diseases. The optimal cut-oﬀ
value for the diagnosis of cirrhosis suggested from the
summary ROC was 13.01 kPa [2] with range from
10.3 kPa in chronic hepatitis B to 17.3 kPa in chronic
cholestatic diseases. According to these results, TE can
be used in clinical practice as an excellent tool for the con-
ﬁrmation of cirrhosis when other clinical signs and exam-
inations are non-decisive.
Recently, we had the opportunity to examine a liver
biopsy (January 2008) taken from a 54 year old dia-
betic, hyperlipidemic patient, with a past history of
myocardial infarction (in 1993 and 1996), triple coro-
nary bypasses (1997), and implantation of a cardiac
deﬁbrillator (2004). This patient was treated with a
long list of medications including diuretics, sugar low-
ering agents, hypotensive drugs. In November 2007
and January 2008, the patient underwent 2 TE satisfac-
tory measurements (Fibroscan) which were surprisingly
high (14.3 and 34.8 kPa, respectively) consistent with
the diagnosis of cirrhosis possibly related to NASH be-
cause of a raised BMI (28), increased GGT (450 IU/L,
normal <61), elevated triglycerides (4.18 mmol/L, nor-
mal <1.7), low HDL ratio (0.74, normal >1). He was
HBV and HCV negative and transaminases were nor-
mal. The probability of cirrhosis was further reinforced
by an elevated Fibrotest (0.84). To conﬁrm the diagno-
sis and the etiology of cirrhosis a liver biopsy was
performed.
Biopsy analysis revealed that the liver architecture was
preserved. In addition, there was major sinusoidal dilata-
tion with a preserved non capillarized sinusoidal endothe-
lial barrier (CD 34/CD31 negative) and a major
sinusoidal ﬁbrosis (reticulin stain) with activated a
smooth muscle actin positive hepatic stellate cells. There
was no portal ﬁbrosis, no septa formation and no argu-
ment for the diagnosis of cirrhois, steatosis or NASH.
Therefore, the ﬁnal diagnosis was cardiac hepatopathy
[3].
The elevated ﬁbrotest value in the cirrhotic range
could be explained by the elevated level of unconjugated
bilirubin (32 lmol/l, normal <18). It is also likely that
sinusoidal ﬁbrosis contributed to the high TE value
[4]. The discrepancy between the 2 TE measurements re-
mains diﬃcult to explain unless liver blood volume and
sinusoidal dilatation controlled by the cardiac pump
plays a major role in stiﬀness.
Curiously, there is no data in the literature concern-
ing TE data related to cardiac hepatopathy, and more
generally to sinusoidal diseases (SOS, haematological
disorders, amyloidosis, etc) or vascular diseases (shunts,
nodular regenerative hyperplasia, etc). The evidence we
can derive from a single case is rather weak. ‘‘ad hoc”
studies are warranted and should be programmed. This
evaluation using this rapid, painless and easy technique
performed at the bedside or in the out-patient clinic is
needed to better deﬁne the correct interpretation of TE
individual data. Indeed, these frequent or rare diseases
may be occasionally encountered in patients with hepa-
titis (B, C, auto immune), HIV infection, NASH, iron
overload or alcohol-related disorders.
Our observation underscores the inherent challenges
to pathologic diagnosis or even the limited assessment
of ﬁbrosis or cirrhosis using a surrogate biochemical
or indirect physical measurements; no alternative alone
can or should be translated literally into the more com-
plex designation of cirrhosis, and neither should the term
ﬁbrosis be used synonymously with cirrhosis [5]. So far
there is now clinical evidence that TE does not measure
ﬁbrosis exclusively (for review see 2).
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Interpreting liver stiﬀness in the cirrhotic range:
What are we measuring?
To the Editor:
We thank Dr. Bioulac-Sage and colleagues for their
interest in our review. The case of cardiac hepatopathy
they report emphasizes the fact that interpretation of
the results of transient elastography (TE) and other
non-invasive tests should always be done by expert clini-
cians according to the clinical context. Indeed, although
the clinical and biological features of this patient could
be consistent with the diagnosis of cirrhosis related to
NASH, the patient had a past history of severe cardiac
disease (myocardial infarction, triple coronary bypasses,
and an implantable cardioverter–deﬁbrillator). No
information regarding physical examination or ultraso-
nography is provided by the authors. The presence of
enlarged liver and/or hepato-jugular reﬂux on physical
examination together with dilated hepatic veins and
inferior vena cava, suggestive of chronic heart failure,
would have helped to anticipate the ﬁndings of liver
biopsy. Although we believe that combining TE with
serum non-invasive markers such as Fibrotest increases
diagnostic accuracy, we emphasize that so far, it has
only been studied in patients with hepatitis C [1]. The
discrepancy between the two TE results is surprising
within such a short period of time (2 months): ‘‘quality
criteria” (interquartile range (IQR) and success rate) for
interpretation of TE results are not provided by the
authors but measurements are said to be satisfactory.
Although TE has been shown to be a reproducible tech-
nique, longitudinal data are still lacking. Preliminary
results regarding liver stiﬀness dynamics in a control
group of untreated patients with chronic hepatitis C sug-
gest that liver stiﬀness values are stable over time [2].
Thus, this discrepancy remains diﬃcult to explain.
As stressed by the authors, it is likely that perisinuos-
idal ﬁbrosis contributed to the increased liver stiﬀness
values. As suggested by morphometric studies [3], liver
stiﬀness seems to accurately reﬂect the amount of liver
ﬁbrosis whatever its location and inﬂuence on liver
architecture. Consistent with this ﬁnding, marked peris-
inusoidal ﬁbrosis was reported in 10 out of 45 patients
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